Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AVITA Medical (RCEL) Gains from Investment Securities (2019 - 2025)

AVITA Medical (RCEL) has disclosed Gains from Investment Securities for 5 consecutive years, with $60132.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Gains from Investment Securities fell 64.63% year-over-year to $60132.0, compared with a TTM value of $60132.0 through Dec 2025, down 33.19%, and an annual FY2025 reading of $60132.0, down 98.3% over the prior year.
  • Gains from Investment Securities was $60132.0 for Q4 2025 at AVITA Medical, down from $5.1 million in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $5.1 million in Q3 2025 and bottomed at -$163000.0 in Q4 2022.
  • Average Gains from Investment Securities over 4 years is $1.1 million, with a median of $163000.0 recorded in 2022.
  • Peak annual rise in Gains from Investment Securities hit 188788.89% in 2024, while the deepest fall reached 103.61% in 2024.
  • Year by year, Gains from Investment Securities stood at -$163000.0 in 2022, then skyrocketed by 1750.4% to $2.7 million in 2023, then tumbled by 93.68% to $170000.0 in 2024, then crashed by 64.63% to $60132.0 in 2025.
  • Business Quant data shows Gains from Investment Securities for RCEL at $60132.0 in Q4 2025, $5.1 million in Q3 2025, and $119482.0 in Q2 2025.